ABSTRACT -We have constructed a large-scale transcriptome database of rat liver treated with various drugs. In an effort to identify a biomarker for interpretation of plasma triglyceride (TG) decrease, we extracted 218 probe sets of rat hepatic genes from data of 15 drugs that decreased the plasma TG level but differentially affected food consumption. Pathway and gene ontology analysis revealed that the genes belong to amino acid metabolism, lipid metabolism and xenobiotics metabolism. Principal component analysis (PCA) showed that 12 out of 15 compounds were separated in the direction of PC1, and these 12 were separated in the direction of PC2, according to their hepatic gene expression profiles. It was found that genes with either large or small eigenvector values in principal component PC 2 were those reported to be regulated by peroxisome proliferator-activated receptor (PPAR)α or constitutive androstane receptor (CAR), respectively. In fact, WY-14,643, clofibrate, gemfibrozil and benzbromarone, reported to be PPARα activators, distributed to the former, whereas propylthiouracil, omeprazole, phenobarbital, thioacetamide, methapyrilene, sulfasalazine and coumarin did to the latter. We conclude that these identified 218 probe sets could be a useful source of biomarkers for classification of plasma TG decrease, based on the mechanisms involving PPARα and CAR.
INTRODUCTION
The toxicogenomics project was a 5-year collaborative project by the National Institute of Biomedical Innovation (NIBIO), the National Institute of Health Science (NIHS), and 15 pharmaceutical companies in Japan that started in 2002 (Urushidani and Nagao, 2005) . Its aim was to construct a large-scale toxicology database of transcriptome for prediction of toxicity of new chemical entities in the early stage of drug development. About 150 chemicals, mainly medicinal compounds, were selected, and gene expression in liver (also kidney in some cases) was comprehensively analyzed by using Affymetrix GeneChip ® . In 2007, the project was finished and the whole system, consisting of the database, the analyzing system and the prediction system, was completed and named as TG-GATEs (Genomics Assisted Toxicity Evaluation System developed by Toxicogenomics Project, Japan).
In toxicity studies, plasma triglyceride (TG) decrease is often observed. Because plasma TG level can be influenced mostly by nutritional status, decrease in food consumption is one of the factors for its change. For activator of peroxisome proliferator-activated receptor (PPAR)α, it is a hot field of drug development, and this drug facilitates the expression of genes related to fatty acid β−oxidation (Schoonjans et al., 1996) , subsequently lowering plasma TG level. Phenobarbital (PB), an antiepileptic barbiturate derivative, decreases plasma TG level but increases plasma total cholesterol without decrease in food consumption in rats (Kiyosawa et al., 2004; Hall et al., 1990) . Kiyosawa et al.(2004) proposed a mechanism of serum cholesterol elevation via up-regulation of hepatic cholesterol synthesis. So far, PB is not reported to be a PPARα activator, and the mechanism of plasma TG decrease by PB is not well understood. In these cases, plasma TG decrease could be a target of the drug in one case, or a sign of toxicity in another case, each with different mechanisms. Thus, identification of the mechanisms behind plasma TG decrease during drug treatment would enable both seed discovery and interpretation of toxicity.
One of the main purposes of TG-GATEs is to identify biomarkers for toxicity evaluation. Although there have been various reports describing strategies to extract marker genes from the transcriptome data (Hibbs et al., 2004; Mutlib et al., 2006; Tan et al., 2006) , the best way has not been established. In the present study, we have started to identify candidates of potential biomarker genes for interpretation of the fundamental mechanism(s) of plasma TG decrease, since our database contains several drugs that cause plasma TG decrease.
MATERIALS AND METHODS

Animals and treatments
Male Crj:CD(SD)IGS rats were purchased from Charles River Japan Inc., (Kanagawa, Japan) at 5-weeks of age. After a 7-day quarantine and acclimatization period, the animals were divided into groups of 5 animals using a computerized stratified random grouping method based on the body weight for each age. The animals were individually housed in stainlesssteel cages in a room that was lighted for 12 hr (7:00-19:00) daily, ventilated with an air-exchange rate of 15 times per hour, and maintained at 21-25°C with a relative humidity of 40-70%. Each animal was allowed free access to water and pellet food (CRF-1, sterilized by radiation, Oriental Yeast Co., Japan). Rats in each group were orally administered with various drugs suspended or dissolved either in 0.5% methylcellulose solution (MC) or corn oil according to their dispersibility. At the time when the present analysis was performed, 15 compounds in our database were found to decrease the plasma triglyceride level during repeated administration (Table 1) . Of these, isoniazid (INAH, 50, 100, 200 mg/kg; MC), phenobarbital (PB, 10, 30, 100 mg/kg; MC), thioacetamide (TAA, 4.5, 15, 45 mg/ kg; MC), benzbromarone (BBr, 20, 60, 200 mg/kg; MC) , methapyrilene (MP, 10, 30, 100 mg/kg: MC), amiodarone hydrochloride (AM, 20, 60, 200 mg/kg; MC), gemfibrozil (GFZ, 30, 100, 300 mg/kg; corn oil) and sulfasalazine (SS, 100, 300, 1000 mg/kg; MC) were purchased from Sigma Aldrich (St. Louis, MO, USA). Alpha-naphthylisothiocyanate (ANIT, 1.5, 5, 15 mg/kg; corn oil) was purchased from Kanto Chemical (Tokyo, Japan). Coumarin (CMA, 15, 50, 150 mg/kg; corn oil), propylthiouracil (PTU, 10, 30, 100 mg/kg; MC) and 643 (WY, 10, 30 , 100 mg/kg; corn oil) were purchased from Tokyo Kasei Kogyo (Tokyo, Japan). Carbon tetrachloride (CCL4, 30, 100, 300 mg/ kg; corn oil), clofibrate (CFB, 30, 100, 300 mg/kg; corn oil) and omeprazole (OPZ, 100, 300, 1000 mg/kg; MC) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Body weights were recorded every day while food consumption was recorded every 4 days during repeated dosing and expressed as g/day. The animals were treated for 3, 7, 14 or 28 days, and they were sacrificed 24 hr after the last dosing. Blood samples were collected to heparinized tube under ether anesthesia from the abdominal aorta after which the animals were sacrificed.
Blood chemistry analysis
Heparinized blood samples were centrifuged at 1,600 × g for 20 min to obtain plasma and the concentration of TG was determined using an automated clinical analyzer (Japan Bioassay Research Center and Anpyo Center; HITACHI 7070, Hitachi Ltd., Food and Drug Safety Center: COBAS MIRA plus, Roche Diagnostics, Bozo Research Center: TBA-120FR, Toshiba Lab Medical, Tokyo, Japan).
Microarray analysis
After collecting the blood, the animals were euthanized by exsanguinations from abdominal aorta under ether anesthesia. An aliquot of the sample (about 30 mg) for RNA analysis was obtained from the left lateral lobe of the liver in each animal immediately after sacrifice, kept in RNAlater ® (Ambion, Austin, TX, USA) overnight at 4°C, and frozen at −80°C until use. Liver samples were homogenized with the buffer RLT supplied in RNeasy Mini Kit (Qiagen, Valencia, CA, USA), and total RNA was isolated according to the Vol. 32 No. 4 manufacturer's instructions. Microarray analysis was conducted on 3 out of 5 samples for each group by using GeneChip ® RAE 230A probe arrays (Affymetrix, Santa Clara, CA, USA), containing 15,923 probe sets. The procedure was conducted basically according to the manufacturer's instructions using Superscript Choice System (Invitrogen, Carlsbad, CA, USA) and T7-(dT)24-oligonucleotide primer (Affymetrix) for cDNA synthesis, cDNA Cleanup Module (Affymetrix) for purification, and BioArray High yield RNA Transcript Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA) for synthesis of biotin-labeled cRNA. Ten micrograms of fragmented cRNA was hybridized to a RAE230A probe array for 18 hr at 45°C at 60 rpm, after which the array was washed and stained by streptavidin-phycoerythrin using Fluidics Station 400 (Affymetrix) and scanned by Gene Array Scanner (Affymetrix). The digital image files were processed by Affymetrix Microarray Suite version 5.0. Microarray image data were analyzed with GeneChip Operating Software (Affymetrix).
Statistical analysis
Plasma TG and food consumption results were expressed as means ± SD. They were analyzed by Bartlett test that evaluates the homogeneity of variance. If the variances were homogenous, ANOVA was applied. If the variances were heterogeneous, KruskalWallis test was performed. When ANOVA resulted in a statistical difference between the groups, Dunnett test was applied. When Kruskal-Wallis test resulted in statistically different groups, Dunnett type mean rank test was performed. Identification of genes related to plasma TG decrease and gene expression data were analyzed by Welch ANOVA for the dose level and applied with Benjamini and Hochberg False Discovery Rate as a multiple-testing correction. In these tests, a significant level at p<0.05 was considered acceptable (Snedecor and Cochran, 1989) .
GeneChip data were normalized by the global median normalization method using GeneSpring version 7 (Agilent Technologies Inc., Palo Alto, CA, USA). Probe sets with present or marginal call in at least 1 of 48 samples (N=3 for 4 time points and 4 dose levels) were selected. Principal component analysis (PCA) of the GeneChip data was performed using Spotfire DecisionSite ver. 8.2 (Spotfire, Somerville, MA, USA).
Pathway and Gene Ontology (GO) analysis
The identified probe sets were subjected to analysis of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and GO analysis by DAVID (Database for Annotation, Visualization, and Integrated Discovery; http://apps1.niaid.nih.gov/david/) using Fisher's exact test (Dennis et al., 2003) . Level 5 analysis was adopted.
RESULTS
Plasma biochemistry and food consumption
Rats were treated with each compound (ANIT, AM, BBr, CCL4, CFB, CMA, GFZ, INAH, MP, OPZ, PB, PTU, SS, TAA and WY) by gavage for up to 4 weeks. The TG concentration and food consumption results are shown in Fig. 1 . All compounds that we selected showed a TG-decreasing property during the dosing period, while their effects on food consumption differed. In BBr-, CMA-, OPZ-and SS-treated animals, food consumption transiently dropped in the first 3 days while it returned to normal thereafter. In AM-, INAH-and TAA-treated rats, food consumption was depressed throughout the dosing period. PTU-treatment decreased food consumption from day 15 whereas MP-treatment decreased at day 29. ANIT-, CFB-, CCL4, GFZ-, PB-, and WY-treatment affected the food intake only slightly.
Identification of genes related to the plasma TGdecreasing property
After filtering the probe sets (with present or marginal call in at least 1 of 48 samples), Welch ANOVA with multiple testing correction was applied to each compound to extract significantly mobilized probe sets. As shown in Table 1 , the numbers of extracted probe sets varied among the compounds, from 640 (AM) to 5,712 (TAA). We then selected the probe sets that were commonly changed from more than 10 out of 15 compounds, and 218 probe sets were obtained. KEGG pathway analysis revealed that pathways related to "proteasome", "fatty acid metabolism", "amino acid metabolism", and "bile acid biosynthesis" were mainly altered in liver treated with these compounds (Table 2 ). GO analysis showed that some groups (other than cellular lipid metabolism) related to xenobiotics metabolism, such as carboxylic acid metabolism, and glucuronosyltransferase and aldehyde dehdrogenase activity, were also affected in liver (Table 3) .
Principal component analysis (PCA)
To assess the expression profiles of identified probe sets, PCA with 218 probe sets for data of all 15 compounds were performed. As shown in Fig. 2 Table 4 , "vanin 1", "similar to Aig1 protein", "CD36 antigen", and "cell death-inducing DNA fragmentation factor, alpha subunit-like effecter A" had large eigenvector values for PC 2. Meanwhile, "glutathione S-transferase A5, aldehyde dehydrogenase family 1, member A1", "liver UDP-glucuronosyltransferase, phenobarbital-inducible form", "carbonic anhydrase 2" and "cytochrome P450, family 2, subfamily b, polypeptide 15" had small values for PC 2 (Table 5) . "Aldehyde dehydrogenase family 1, member A1", "glutathione S-transferase A5", "vanin 1", "carboxylesterase 2 (intestine, liver)" and "CD36 antigen" had smaller eigenvector values for PC 1 (Table 6) . Six-week-old male Sprague-Dawley rats were gavaged with each compound for 3, 7, 14 or 28 days, and they were sacrificed 24 hr after the last dosing. Food consumption was recorded every 4 days during dosing and blood samples were collected at sacrifice. Plasma TG concentrations were estimated as described in materials and methods. For simplicity, the data of the highest dose were presented for each compound. Open (control) and filled (treated) columns represent plasma TG concentration. Open (control) and filled (treated) circles represent food consumption. Values are expressed as mean ± SD of 5 rats each for each time and compound. Significant difference from control rat: (*p<0.05, **p<0.01: Dunnett test, #p<0.05, ##p<0.01: Dunnett type mean rank test). MP-food consumption on day 4 was not determined.
As PC 2 was considered to be indirectly related to cholesterol metabolism (see DISCUSSION), three compounds with the smallest values for both PC 1 and PC 2, i.e., PB, OPZ and PTU were selected, and their effects on plasma cholesterol level are shown in Fig. 3 . It is obvious from the figure that OPZ and PTU, which had smaller PC 2 values than PB, significantly increased plasma cholesterol.
DISCUSSION
Lowering of the plasma TG level is often observed in rat toxicity studies. It would be useful to elucidate its mechanism not only for safety evaluation of drugs but also for finding seeds of lipid-lowering agents. In the course of our trials to identify useful toxicity biomarkers from our large-scale database, we selected plasma TG decrease as a toxicological phenotype, and picked up 15 such compounds from 40 (the number of compounds available at the time when the Table 2 . KEGG pathways of the identified 218 probe sets related to plasma TG. present analysis was performed). Since our database has a broad variety of compounds for hepatic toxicity, each compound has different properties for drug efficacy and toxicity (Table 1) .
As shown in Fig. 1 , the effects of these compounds on food consumption were not similar. It is well known that plasma TG levels depend largely upon nutrition, and the results suggested that there should have been multiple factors other than a simple general toxicity. To clarify the multiple mechanisms in plasma TG homeostasis, we extracted 218 probe sets as commonly changed genes in more than 10 out of 15 compounds (commonly changed in two-thirds of the compounds). The fact that there were no probe sets commonly changed in all the compounds (data not shown) also suggested that there are multiple factors involved in the mechanism of plasma TG decrease.
KEGG pathway analysis suggested that the proteasome-, fatty acid metabolism-, tryptophan metabolism-, bile acid biosynthesis-, and histidine metabolism-related pathways were involved (Table 2) . Since TG is an important source of energy, it is understood PCA of gene expression profiles was performed using identified 218 probe sets for the data of the highest dose of 15 compounds at various time points. The selection of the 218 probe sets related to plasma TG decrease is described in materials and methods. The values used in the analysis were the normalized signal values. Each spot represents the mean of the normalized gene expression value. The abbreviation for each drug is summarized in Table 1 . The eigenvalue, percent variability, and cumulative variability for PC 1 and PC 2 are shown in the table on the lower right corner.
that pathways related to energy homeostasis such as fatty acid synthesis and amino acid metabolism were affected. GO analysis showed that the carboxylic acid metabolism-and glucuronosyltransferase activityrelated genes were also affected by TG-decreasing compounds (Table 3) . UDP-glucuronosyltransferase, one of the extracted genes, is of major importance in conjugation and subsequent elimination of potentially toxic xenobiotics (Bock et al., 1990) . PB and OPZ, which lowered plasma TG level in the present study, were previously reported to have the ability to induce this enzyme (Bock et al., 1990; Masubuchi et al., 1997) . These results indicated that the xenobiotics metabolism pathway might have a role in plasma TG decrease.
To examine the basis of the gene expression profile of each sample, we performed PCA on hepatic gene expression profiles of the 15 compounds. In PCA, three clear clusters were identified (Fig. 2) . All compounds except ANIT, CCL4 and INAH were uniformly dispersed into smaller PC 1 with either large or small PC 2, i.e., WY, BBr, GFZ and CFB were dispersed into small PC 1 with large PC 2, whereas PTU, OPZ, PB,MP, TAA, SS and CMA into small PC 1 with small PC 2. AM was exceptionally found in the middle position of PC 2. In PC 2, "vanin 1", "similar to Aig1 protein", "CD36 antigen", "cell death-inducing DNA fragmentation factor, and alpha subunit-like effecter A (CIDEA)" had larger eigenvector values ( Table 4) , meaning that these genes made a great contribution to increasing PC 2 values in each liver sample. Vanin 1 is Table 4 . Top five probe sets with the largest eigenvector values for second principal component in the PCA shown in Fig. 2 . reported to be involved in lymphocyte migration in cell adhesion during colonization of the thymus by hematopoietic precursor cells, and also has pantetheinase activity (Pitari et al., 2000) . Though vanin 1 is not reported to play a role in lipid metabolism so far, it was in fact reported to be an inducible gene by PPARα (Yamazaki et al., 2002) .
CD36 antigen (fatty acid translocase (FAT)) is involved in regulating the uptake of fatty acid across the plasma membrane (Bonen et al., 2004) and also reported to be induced by PPARα agonists in liver (Motojima et al., 1998) . Moreover, it has been reported that CD36 plays a role in plasma TG homeostasis via modulation of LPL activity (Goudriaan et al., 2005) . Thus, an increase of this gene expression would be one of the mechanisms of plasma TG level decrease in the corresponding animal.
A previous report described that CIDEA-null mice presented TG decrease in fasting condition compared with wild type (Zhou et al., 2003) . Because expression of the CIDEA gene was up-regulated in liver treated with TG-decreasing compounds in both principal components (data not shown), it seemed to be a compensatory reaction. In addition, compounds with large PC 2 values, i.e., WY, GFZ, CFB and BBr, are reported to be agonists of PPARα (Kunishima et al., 2003; van Raalte et al., 2004) . Activation of PPARα induces hepatic gene expression by β-oxidation of fatty acid and hydrolysis of TG-rich lipoprotein via activation of peripheral lipoprotein lipase (LPL) (van Raalte et al., 2004) . In addition to activation of fatty acid β-oxidation, PPARα inhibits de novo fatty acid synthesis in liver (Schoonjans et al., 1996) . In peripheral tissue, it has also been reported that gene expression of APOC3 (a natural inhibitor of LPL activity) decreases by PPARα and subsequently LPL activity is increased (Staels et al., 1995) . Taken together, these results suggest that the trend of increasing PC 2 is linked to lowering plasma TG level via PPARα activation.
"Glutathione S-transferase A5", "aldehyde dehydrogenase family 1, member A1", "liver UDP-glucuronosyltransferase, phenobarbital-inducible form", "carbonic anhydrase 2", "cytochrome P450, family 2, subfamily b, polypeptide 15" had smaller eigenvector values for PC 2 (Table 5) . They (except carbonic anhydrase 2) have been reported to be constitutive androstane receptor (CAR)-inducible genes (Kakizaki et al., 2003) . Although there is no report that PTU, OPZ, TAA, MP, SS and CMA activate CAR so far, the present results suggested that these compounds could Fig. 3 . Effects of PB, OPZ, PTU on plasma total cholesterol level.
Plasma total cholesterol concentrations were estimated as described in materials and methods. Open (control) and filled (treated) columns represent total plasma cholesterol concentration. Values are expressed as mean ± SD of 5 rats for each time and compound. Significant difference from control rat: (*p<0.05, **p<0.01: Dunnett test).
induce the same xenobiotics metabolizing enzymes as PB does (Kakizaki et al., 2003) . Meanwhile, these enzymes (such as UDP-glucuronosyltransferase) are able to metabolize not only xenobiotics but also serum thyroid hormone (TH) (Qatanani and Moore, 2005) , which has a role in comprehensive regulation of energy metabolism (Weiss et al., 1998) . It has been reported that rats with hypothyroidism induce and activate peripheral lipoprotein lipase (LPL), the key enzyme in hydrolysis of TG-rich lipoproteins, such as chylomicron and VLDL (Kern et al., 1996; Ong et al., 1994) . In fact, it has also been reported that PB, PTU and OPZ are able to alter blood TH level (Masubuchi et al., 1997; De Sandro et al., 1991) . CAR is also activated by caloric restriction (Maglich et al., 2004) . With depletion of food, the body needs to lower its energy requirement. It might be possible that CAR was activated in rats whose food consumption was decreased (Fig. 1) . Thus, identified probe sets might be indirectly related to plasma TG decrease via reduction of blood TH by CAR activation in at least two ways. Accordingly, the feature in decreased PC 2 value could be related to lowering plasma TG level via CAR activation. Moreover, it has been reported that TH is a physiological regulator of cholesterol metabolism (Weiss et al., 1998; Gullberg et al., 2000 Gullberg et al., , 2002 Hashimoto et al., 2006; Ness and Chambers, 2000) and hypercholesterolemia is found in patients with hypothyroidism (Diekman et al., 2000) . It was also noted in the present study that total cholesterol levels in OPZ and PTU with smaller PC 2 values were found to be increased (Fig.  3 ). These indirect evidences also supported the assumption that TH levels were involved in plasma TG reduction.
As shown in Table 6 , genes with smaller eigenvector values for PC 1 such as "aldehyde dehydrogenase A5", "glutathione S-transferase A5", "vanin 1", "carboxylesterase 2" and "CD36 antigen" were important genes that contribute to shift each sample to either direction of PC 2. It appears that PC 1 shows a lowering of plasma TG level via either or both of two mechanisms (PPARα and/or CAR activation). Interestingly, AM had small PC 1 values, while near zero in PC 2. This result is supported by previous reports that AM induces the expression of PPARα target genes (McCarthy et al., 2004) and lowers serum TH level (De Sandro et al., 1991) . Thus, these two directions might have been balanced in the case of the plasma TG reduction by AM.
It was previously reported that PPARα was also activated by fasting (Kersten et al., 1999; Lee et al., 2004; Leone et al., 1999) , as well as by CAR. An interesting question is why these 218 probe sets classify the compounds with various pharmacological and toxicological properties based on their different mechanisms. Genes with the largest or smallest eigenvector values for PC 2 such as vanin 1 and glutathione S-transferase A5 are related to each nuclear receptor, PPARα and CAR, respectively, rather than to plasma TG homeostasis. CD36, which was involved in regulating the uptake of fatty acid, mainly contributed to PC 1. This means that CD36 could be an important gene directly related to plasma TG level, while its background mechanisms are represented by genes like vanin 1 or glutathione S-transferase A5. Thus, we considered that these probe sets work to classify the compounds by PCA, based on each nuclear receptor-mediated TGlowering mechanism.
In the present study, some compounds such as ANIT, CCL4 and INAH were not dispersed in PCA, suggesting potential involvement of other TG-decreasing mechanism(s). Because the plasma TG level is influenced by the balance of intake from diet, hepatic synthesis, secretion from liver, and metabolism at peripheral tissues, many factors remain to be investigated. Moreover, since it has been reported that the action of TH on LPL activity is in the opposite direction between human and rat (Kern et al., 1996; Ong et al., 1994) , it is necessary to elucidate the species difference in the mechanism of plasma TG decrease.
In conclusion, we identified 218 probe sets from gene expression profiles in liver treated with various TG-decreasing compounds stored in our database. Analysis of identified probe sets suggested two mechanisms in plasma TG decrease, i.e., PPARα and CAR activation, in addition to at least one unknown mechanism. The proposed mechanisms of lowering plasma TG level elucidated by the present study are summarized and depicted in Fig. 4 . Further studies, especially verifying experiments, are clearly necessary to confirm our hypothesis and to establish useful biomarker genes. The presently extracted probe sets could be a source of potential biomarkers for development of a novel hypolipidemic agent and/or interpretation of the mechanism of plasma TG reduction.
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